Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the idea of naturally lowering testosterone levels to potentially reduce DHT and help with hair loss, though it is speculative and not tested by the original poster. Participants suggest using treatments like finasteride, dutasteride, or RU58841 instead, as they directly target DHT without reducing testosterone.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.

Whey protein may slightly increase hair loss in men with androgenetic alopecia (AGA) due to elevated IGF-1 and testosterone levels, but the effect is minimal compared to treatments like finasteride and dutasteride. Many users argue that whey protein's impact on hair loss is negligible and that maintaining a healthy lifestyle is more important.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

A user's experience with using Fin for hair loss, which includes shedding and regrowth, potential side effects, and the use of supplements, protein, and exercise as additional treatments.

Creatine may cause hair shedding and texture changes, with mixed user experiences. Combining creatine with finasteride doesn't always prevent these effects, possibly due to individual DHT sensitivity.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

A user reported that after experiencing hair thinning, they started using finasteride in 2024 and later began GHK-Cu peptide injections in March 2026, which they believe stopped their hair loss and made their hair feel thicker. The user shared their experience despite receiving criticism for not solely endorsing finasteride.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

The post is about whether there is any additional benefit to using alfatradiol or other estrogen treatments for hair loss if someone is already using finasteride, dutasteride, or an androgen receptor inhibitor like RU58841, pyrithione zinc, or fluridil.

A user experienced increased shedding after adding KX-826 to their long-term finasteride and minoxidil regimen. Another user reported mild side effects from KX-826, such as stomach and testicle pain.

Using DIM and Calcium D-Glucarate to reduce finasteride side effects. Discussion includes dosage, brand, and product effectiveness.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

People worrying about hair loss and the effects of Finasteride on erections, which a transgirl has experienced no change from taking it with other medications. The discussion suggests that people should stop worrying so much.

The conversation discusses a 20-year-old transgender female's one-year experience with hair loss treatments, including Estradiol HRT, oral Finasteride, Bicalutamide, and Cyproterone. Specific treatments used for hair loss are oral Finasteride and potentially Estradiol as part of hormone replacement therapy.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

Teak leaf extract shows potential as a mild hair growth promoter for androgenic alopecia, with similar positive trends to minoxidil but without significant side effects. It can be made at home using dried teak leaves and ethanol, though its effectiveness compared to other treatments like finasteride is debated.

A 23-year-old male is considering starting Finasteride for hair loss after experiencing persistent shedding and hairline recession, with bloodwork showing normal testosterone levels but low DHEA-S and Vitamin D. He plans to discuss DHEA supplementation with his doctor and has already started Vitamin D supplementation.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

A user shared their experience with high cholesterol, glucose, and potential metabolic syndrome after using Finasteride and Dutasteride for hair loss. They plan to improve their health with diet and exercise before considering medication.

The user is using finasteride and minoxidil for hair loss but is looking for new treatments. Pyrilutamide and GT20029 are potential future treatments, with Pyrilutamide expected next year and GT20029 possibly by 2027.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

Finasteride and minoxidil are commonly recommended by hair transplant clinics, including those in Turkey, despite some negative perceptions and concerns about side effects. The conversation highlights differing opinions on the effectiveness and safety of these treatments, with some users expressing skepticism about side effects and others emphasizing the importance of these medications for successful hair transplants.

The user has been using finasteride and minoxidil since October 2023 and is concerned if a supplement containing L-arginine, L-citrulline, Tongkat Ali, Tribulus terrestris, Avena Sativa, Gingko Biloba, Ginseng, Pyridoxine, Zinc Gluconate, and Saw Palmetto can cause hair loss. They report thicker and denser hair despite ongoing shedding.

The conversation discusses using topical liposomal finasteride for hair loss, with concerns about high DHT levels. The user's DHT level is above the normal range, which may affect hair health.

Sulforaphane, found in broccoli sprouts, promotes hair growth by degrading DHT. Users discuss its potential benefits and joke about unconventional application methods.